F5016
Anti-Human IgG (Fc specific)−FITC antibody, Mouse monoclonal
clone HP-6017, purified from hybridoma cell culture
Sinônimo(s):
Monoclonal Anti-Human IgG (Fc specific)
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Código UNSPSC:
12352203
NACRES:
NA.46
Produtos recomendados
fonte biológica
mouse
Nível de qualidade
conjugado
FITC conjugate
forma do anticorpo
purified from hybridoma cell culture
tipo de produto de anticorpo
secondary antibodies
clone
HP-6017, monoclonal
Formulário
buffered aqueous solution
reatividade de espécies
rabbit, sheep, horse (IgG), goat, human
condição de armazenamento
protect from light
técnica(s)
dot immunobinding: 1:16
particle immunofluorescence: 1:16
Isotipo
IgG2a
Condições de expedição
dry ice
temperatura de armazenamento
−20°C
modificação pós-traducional do alvo
unmodified
Procurando produtos similares? Visita Guia de comparação de produtos
Descrição geral
Monoclonal Anti-Human IgG (mouse IgG2a isotype) is derived from the hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Immunoglobulins (Igs) belongs immunoglobulin super-family. Each immunoglobin have two heavy (H) and two light (L), held together by disulphide linkages. The light comprises of one variable N-terminal region and a constant C-terminal region. The heavy chain has one variable N-terminal region and three or four constant (CH1-CH4) C-terminal region.
Especificidade
The antibody is specific for the Fc portion of human IgG and recognizes an epitope common to all human IgG subclasses. This antibody was adopted as an Fc specific reagent in the IUIS/WHO study.
Aplicação
Monoclonal Anti-Human IgG (Fc specific)-FITC antibody produced in mouse has been used in:
- Fluorescent Dot Immunobinding Assay (F-DIBA)
- Particle Immunofluorescent Assay (F-IFMA)
- flow cytometry
Ações bioquímicas/fisiológicas
Digestion of IgG by papain results in generation of fragment antigen binding (Fab) comprising one complete L chain and a variable and CH1 region of H chain. Pepsin digestion of IgG results in fragment crystallisable (fc), containing the H chain constant region. IgG antibody have enormous therapeutic potential and the Fc is for the development of therapeutic antibody. Although the antibody site is located in the terminal end of the human IgG molecule (part of the Fab fragment), the Fc portion has various important functions such as complement fixation, site for rheumatoid factor (autoantibodies directed to Fc), passage through placental membrane and staphylococcus protein A binding.
forma física
Solution in 0.01 M phosphate buffer pH 8.0, containing 1% inactivated bovine serum albumin and 15 mM sodium azide.
Exoneração de responsabilidade
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Não está encontrando o produto certo?
Experimente o nosso Ferramenta de seleção de produtos.
Palavra indicadora
Danger
Frases de perigo
Declarações de precaução
Classificações de perigo
Resp. Sens. 1 - Skin Sens. 1
Código de classe de armazenamento
12 - Non Combustible Liquids
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Escolha uma das versões mais recentes:
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Os clientes também visualizaram
Martin Pool et al.
European journal of nuclear medicine and molecular imaging, 44(8), 1328-1336 (2017-03-21)
c-MET and its ligand hepatocyte growth factor are often dysregulated in human cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or emergence of resistance. Noninvasive visualization of c-MET dynamics could therefore potentially guide c-MET-directed therapies. We
Jacoba van Zanten et al.
Cancer gene therapy, 11(2), 156-164 (2003-12-27)
In this study, we developed a nonviral, cationic, targeted DNA-carrier system by coupling SAINT/DOPE lipids to monoclonal antibodies. The two monoclonal antibodies used were both tumor specific, that is, MOC31 recognizes the epithelial glycoprotein EGP-2 present in carcinomas and Herceptin
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging
Dijkers ECF, et al.
Journal of Nuclear Medicine, 50(6), 974-981 (2009)
Eli C F Dijkers et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 50(6), 974-981 (2009-05-16)
The anti-human epidermal growth factor receptor 2 (HER2/neu) antibody trastuzumab is administered to patients with HER2/neu-overexpressing breast cancer. Whole-body noninvasive HER2/neu scintigraphy could help to assess and quantify the HER2/neu expression of all lesions, including nonaccessible metastases. The aims of
A nonviral carrier for targeted gene delivery to tumor cells
van Zanten J, et al.
Cancer Gene Therapy, 11(2), 156-156 (2004)
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica